期刊文献+

新疆地区非瓣膜性心房颤动患者抗凝现状及CHADS2与CHA2DS2-VASc评分比较研究 被引量:5

A study on the evaluation of anticoagulation status comparing of CHADS2 versus CHA2DS2-VASc scores in patients with non valvular atrial fibrillation in Xinjiang area
原文传递
导出
摘要 目的 调查新疆地区心房颤动(房颤)患者抗凝现状,并对两种评分系统进行比较,找出更适合新疆地区房颤患者卒中风险评估方法.方法 采用查询电子病历及存档病历的方式,对2013年10月-2014年10月期间新疆地区35家医院的住院病历进行全面筛选,筛选出出院诊断为房颤的病例,随访10~ 12个月,统计卒中发生人数.结果 共入选5 953例房颤患者,年龄(67.9±12.0)岁,男∶女=1.44∶1.60 ~69岁与70 ~79岁两个年龄组人数最多,分别占23.92%及37.81%.CHADS2评分≤1分的患者改用CHA2 DS2-VASc重新评分后得分为0~3分,随访10~12个月后有22例新发卒中.需要接受抗凝的人数为4 742例,实际仅有1 460例患者接受抗凝治疗,抗凝率为30.79%.接受抗凝治疗的患者中,1 162例接受华法林治疗,298例接受新型口服抗凝药治疗.使用华法林患者中,进行国际标准化比值(INR)检测有1 110例,INR中位数为1.14,达到指南推荐INR值2.0~3.0稳态的仅为97例,达标率为8.74%.结论 新疆地区房颤抗凝现状表现为“低抗凝率”“低达标率”的特点;CHA2 DS2-VASc评分更适合新疆地区房颤患者卒中风险预测. Objective To evaluate the current status of anticoagulation therapy in patients with atrial fibrillation(AF) in Xinjiang,and compare the two scoring systems (CHADS2 and CHA2DS2-VASc scores) in determining the risk of strokes in AF patients in Xinjiang.Methods Subjects with AF were collected by searching the electronic and paper medical records from 35 hospitals in Xinjiang area during October 2013 to October 2014,and followed up for the incident strokes after 10 to 12 months.Results Totally,5 953 AF patients were enrolled in the study with the age of (67.9 ± 12.0) years old,and men to women ratio of 1.44.Most patients were in age groups of 60-69 (23.92%) and 70-79 years (37.81%).Among patients with a CHADS2 score of 1 or less,the CHA2 DS2-VASc scores of these subjects ranged from 0 to 3.After 10 to 12 months of follow-up,22 patients developed new strokes.Only 30.79% patients (n =1 460) received the anticoagulation treatment among those (n =4 742) who need to be treated with anticoagulation drugs.In patients receiving anticoagulant therapy,1 162 patients were treated with warfarin,and 298 patients with new oral anticoagulant drugs.Totally 1 110 patients treated with warfarin were monitored with international normalized ratio (INR).The median INR was 1.14 with only 97 cases meeting the recommended INR ranging of 2.0-3.0 in the guidelines.The compliance rate was 8.74%.Conclusions The current status of anticoagulation for AF in Xinjiang area is characterized by "low anticoagulation rate" and "low compliance rate".The CHA2 DS2-VASc score is more suitable for predicting the risk of strokes in patients with non valvular atrial fibrillation in Xinjiang area.
出处 《中华内科杂志》 CAS CSCD 北大核心 2016年第9期684-688,共5页 Chinese Journal of Internal Medicine
基金 新疆维吾尔自治区科技计划项目(20333117)
关键词 心房颤动 流行病学 抗凝治疗 Atrial fibrillation Epidemiology Anticoagulant therapy
  • 相关文献

参考文献20

  • 1胡大一,张鹤萍,孙艺红,姜立清.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,34(4):295-298. 被引量:162
  • 2Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Frarningham Study [ J ]. Stroke, 1991,22 (8) :983-988.
  • 3Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study[ J ]. BMJ, 2011,342 : d124.
  • 4Mazzini M J, Monaban KM. Pharmacotherapy for atrial arrhythmias: present and future [ J ]. Heart Rhythm, 2008,5 ( 6 Suppl) :$26-31. DOI: 10. lO16/j, hrthm. 2008.01. 023.
  • 5Nattel S. New ideas about atrial fibrillation 50 years on [ J 1. Nature, 2002,415(6868) :219-226. DOI: 10. 1038/415219a.
  • 6Chen LY, Shen WK. Epidemiology of atrial fibrillation : a current perspective [ J]. Heart Rhythm, 2007,4 ( 3 Suppl ) : S1-6. DOI : 10. 1016/j. hrthm. 2006.12. 018.
  • 7Huisman MV, Lip GY, Diener HC, et al. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long- term oral antithrombotic treatment in patients with atrial fibrillation [J]. Am Heart J, 2014,167(3):329-334. DOI: 10.1016/j. ahj. 2013.12. 006.
  • 8Kakkar AK, Mueller I, Bassand JP, et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke : Global Anticoagulant Registry in the FIELD (GARFIELD) [J]. Am Heart J, 2012,163( 1 ) :13-19. e1. DOI: 10. 1016/j. abj. 2011.09.011.
  • 9Yuan CS, Wei G, Dey L, et al. Brief communication: American ginseng reduces warfarin' s effect in healthy patients : a randomized, controlled Trial [ J]. Ann Intern Med, 2004, 141 ( 1 ) :23-27.
  • 10华法林抗凝治疗的中国专家共识[J].中华内科杂志,2013,52(1):76-82. 被引量:598

二级参考文献27

  • 1周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量:1398
  • 2张学义,张薇,郑兆通,钟明,黎莉,张运.非瓣膜性心房颤动并发缺血性脑卒中的防治[J].中华急诊医学杂志,2004,13(9):592-594. 被引量:21
  • 3胡大一,张鹤萍,孙艺红,姜立清.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,34(4):295-298. 被引量:162
  • 4Arboix A,Lluis GE,Massons JB,et al.Atrial fibrillation and stroke:clinical presentation of cardioembolic versus atherothrombotic infarction.Int J Cardiol,2000,73:33-42.
  • 5Petersen P,Boysen G,Godtfredsen J,et al.Placebo controlled,randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation.Lancet,1989,338:175-179.
  • 6European Atrial Fibrillation Trial Study Group.Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke.Lancet,1993,342:1255-1262.
  • 7Stroke Prevention in Atrial Fibrillation Investigators.Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation:stroke prevention in atrial fibrillation Ⅱstudy.Lancet,1994,343:687-691.
  • 8Gullov AL,Koefoed BG,Petersen P,et al.Fixed mini-dose warfarin and aspirin alone and in combination versus adjusted-dose warfarin for stroke prevention in atrial fibrillation:Second Copenhagen Atrial Fibrillation,Aspirin,and Anticoagulation Study.Arch Intern Med,1998,158:1513-1521.
  • 9Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia.The European Atrial Fibrillation Trial Study Group.N Engl J Med,1995,333:5-10.
  • 10Hirsh J, Fuster V, Ansell J, et al. American Heart Association/ American College of Cardiology Foundation guide to warfarin therapy. J Am Coil Cardiol, 2003,41:1633-1652.

共引文献749

同被引文献33

引证文献5

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部